We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
NeuroScientific Biopharmaceuticals (ASX:NSB) has received feedback and guidance from the US...
Read ArticleThe ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL Small Ca...
Read ArticleNeuroscientific Biopharma to have a pre-IND meeting with US FDA The NSB stock price jumped as high...
Read ArticleThe ASX200 finished off the first day of December down 0.2 of a percent – with all sectors, except e...
Read ArticleKing Charles III loses coveted job of lurking on Australia’s $5 notes Adani down in the dumps after...
Read ArticleNeuroScientific Biopharmaceuticals (NSB) pockets a $3.7 million tax refund from the Australian Feder...
Read ArticleNSB files new patent in Australia Imugene doses first patient in Phase 1 trial Cronos and MGC Pharm...
Read ArticleNeuroScientific Biopharmaceuticals (NSB) appoints Paul Rennie as interim CEO, nearly three months af...
Read ArticleThe ASX is poised to open higher on Wednesday after a rally in New York Oil prices higher as Saudi...
Read ArticleNeuroScientific Biopharmaceuticals (NSB) CEO and Managing Director Matt Liddelow resigns from the co...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleNeuroscientific Biopharmaceuticals (NSB) astounds investors this morning with the news its phase one...
Read ArticleActing out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxi...
Read ArticleNeuroscientific Biopharma’s receipt of $1.13m in R&D tax incentive from the government is timely...
Read ArticleNeuroscientific Biopharmaceuticals CEO and MD Matthew Liddelow says the company has entered one of t...
Read ArticleNeuren’s Phase 2 clinical trial is now open for enrolment Neuroscientific submits an ethics approva...
Read ArticleNeuroScientific Biopharmaceuticals (ASX:NSB) says it has submitted an application for Human...
Read ArticleNeuroScientific Biopharmaceuticals (NSB) recruits its first subject for an early-phase clinical tri...
Read ArticleNeuroScientific Biopharmaceuticals (ASX:NSB) has announced the recruitment of the first subj...
Read ArticleNeuroScientific Biopharmaceuticals (ASX:NSB) has announced positive preliminary results of l...
Read ArticleHighlights Investors are looking at clean energy stocks as the world is increasingly shifting fr...
Read ArticleHighlights NeuroScientific has received positive preliminary results from a study of its lead dr...
Read ArticleShareCafeLunch Report: 15 June, 2022 The Australian sharemarket has extended its fall for a fourth s...
Read Article15 Jun 2022 - A snapshot of the stocks on the move featuring NeuroScientific Biopharmaceuticals (ASX...
Read ArticleNeuroscientific announce positive results of EmtinB in mice model Island Pharma appoints new drug m...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleNeuroScientific Biopharmaceuticals (NSB) reports “positive” preliminary results from an animal stud...
Read ArticleHighlights The HREC gave a green signal to NeuroScientific for conducting an early-phase clinica...
Read ArticleOrthocell’s nerve reconstruction trial shows encouraging results Neuroscientific gets ethics approv...
Read ArticleNeuroScientific Biopharmaceuticals (ASX:NSB) has submitted an application seeking approval f...
Read ArticleIDX snaps up QLD-based radiology group for circa $38m NSB starts HREC review process Credit Suiss...
Read ArticleNeuroScientific Biopharmaceuticals (NSB) is on schedule to begin the clinical development of its le...
Read ArticleNeuroScientific Biopharmaceuticals (ASX:NSB) has reported positive outcomes from its preclin...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleNeuroScientific Biopharmaceuticals (NSB) confirms the safety of its lead drug candidate, EmtinB The...
Read ArticleOkay, who poked the S&P/ASX Emerging Companies index (XEC) this morning? Someone woke the sleepi...
Read ArticleOncosil’s medical device is being used commercially for the first time in Europe NeuroScientific Bi...
Read ArticleNeuroScientific Biopharmaceuticals (NSB) completes an assessment of its lead drug candidate EmtinB...
Read ArticleASX to fall, US inflation highest in 40 years US inflation soared to 7.9% in the past year, outpacin...
Read ArticleNeurotech International (NTI) appoints Alexandra Andrews as Chief Executive Officer (CEO), effectiv...
Read ArticleNeuroScientific Biopharmaceuticals (ASX:NSB) share price jumped ~13% today to 35 cents after an upda...
Read ArticleNeuroScientific Biopharmaceuticals (NSB) completes two studies involving its lead drug candidate, E...
Read ArticleNeuroScientific Biopharmaceuticals (ASX:NSB) has reported outcomes from recently completed i...
Read ArticleASX to open flat amid late sell off in US tech Wall Street mainly finished lower on Monday as a late...
Read ArticleThe price action of ASX biotech shares was nothing short of a mixed bag in 2021. Several of the ma...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleThe Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price is rising today on the back of a...
Read ArticleThe ASX 200 Health Index (XHJ) is trading higher by 0.70% at the time of writing, compared to the br...
Read ArticleNeuroScientific Biopharmaceuticals (NSB) reports positive results from off-target safety assessment...
Read ArticleWall Street gains for third consecutive day US stocks staged a pre-Christmas rally as omicron fears...
Read ArticleShareCafeWebinar Recap – ECT, ATV, TZL, AO1 Catch up on the full webinar with presentations from En...
Read ArticleShareCafeNeuroScientific Biopharmaceuticals (ASX: NSB) – Webinar Presentation Alexandra Andrews –...
Read ArticleIt’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for in...
Read ArticleThe broad Australian indices have started the day off in the red as the market resets from a number...
Read ArticleShareCafeHidden Gems Webinar Recap – CYP, AT1, NSB & KZA Catch up on the full webinar with pre...
Read ArticleShareCafePeptide based therapies for neurodegenerative conditions Dougal Thring – VP Clinical...
Read ArticleNeurological disorder specialist, Neuroscientific Biopharma (ASX:NSB), announced that research work...
Read ArticleThe breakthrough announcement by NeuroScientific Biopharma today elevates its lead drug EmtinB to hu...
Read ArticleS&P 500 and Nasdaq at record highs again The US stock markets are coming home for a strong finis...
Read ArticleLeading the health stocks today is Nanosonics (ASX:NAN) up 19.69% after flagging FY21 revenues of $...
Read ArticleAnother red day for the ASX to close out the week. The ASX 200 closed 0.05% down from yesterday at 7...
Read ArticleThe Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price jumped higher this morning before...
Read ArticleThe broader ASX continued its losing streak, shedding another 0.5% while the benchmark ASX 200 close...
Read ArticleGot 90 seconds? Then listen to Chairman, Paul Rennie tell us about their company news. Neuroscientif...
Read ArticleIt wasn’t a happy start to the new financial year for Australia’s bourse, which lost nearly two thir...
Read ArticleNeuroScientific Biopharmaceuticals Ltd (ASX: NSB) shares jumped more than 7% in early trade after t...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read Article23 Jun 2021 - A snapshot of notable stock news for the hour, featuring ikeGPS Group, Wide Open Agric...
Read Article23 Jun 2021 - NeuroScientific Biopharmaceuticals (ASX:NSB) has partnered with Linear Clinical Resear...
Read ArticleSummary The ASX 200 traded lower by 27.30 points or 0.37% at 7,314.90 by afternoon, led by energ...
Read ArticleNeuroScientific Biopharmaceuticals (ASX:NSB) edged even closer to a planned Phase I clinical trial o...
Read ArticleWall Street rebounds as Nasdaq resets record high All three major US benchmarks rose overnight, as i...
Read ArticleAfter overseeing Paradigm Biopharmaceuticals’ (ASX:PAR) rise to 14-bagger highs, Paul Rennie has joi...
Read ArticleTech stocks lead global sell-off Tech and growth stocks mostly fell overnight, after US Treasury Sec...
Read ArticleWall Street pulls back as tech stocks retreat All the major US indices fell last night. Dow Jones wa...
Read ArticleSummary Neuroscientific Biopharmaceuticals is collaborating with The Institute of Respiratory Hea...
Read ArticleThe company is partnering with The Institute of Respiratory Health and The University of Western Aus...
Read ArticleThe company has received strong commitment for the placement, whose proceeds will be used to finish...
Read ArticleSpecial Report: Early stage biotech NeuroScientific Biopharmaceuticals is developing peptide-based c...
Read ArticleThe Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price is up 20% today on the back of an...
Read ArticleNeuroScientific Biopharmaceuticals (ASX: NSB) has published positive preliminary results from a pre-...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleBackpackers in Bondi were pilloried for spreading COVID-19, but everyone knows gonorrhoea is a great...
Read ArticleOur summary of NeuroScientific Biopharmaceuticals Ltd's recent announcement What's happened? NeuroSc...
Read ArticleThe COVID-19 pandemic will result in changes to several industries and one of these is manufacturing...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small ca...
Read ArticleNeuroScientific Biopharmaceuticals (ASX: NSB) has achieved positive results in pre-clinical studies...
Read ArticleNeuroScientific Biopharmaceuticals (ASX: NSB) has revealed positive results from a glaucoma study on...
Read ArticleDementia already affects hundreds of thousands of people in Australia, and it’s only going to get wo...
Read ArticleImpediMed’s (ASX:IPD) December quarter report includes the word ‘up’ eight times and the word ‘down’...
Read ArticleYou may have heard the saying “it’s not brain surgery” in the context of trying to prove something e...
Read ArticleAsia is rising as a healthcare spender, matching incomes and the long-feared elderly population boom...
Read ArticleCancer is a crowded market, pot has sleep and pain issues covered — or so they say — and companies d...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleIt can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve smal...
Read ArticleInvestors, brokers, high-ranking delegates, big pharma and Aussie small caps will all be sharing a r...
Read ArticleSpecial Report: The inaugural Biotech Luncheon in Perth launched with a bang, with more than 150 gue...
Read ArticleThe WA investment community will turn its attention to healthcare next Thursday, when the annual Bio...
Read ArticleDrug developer NeuroScientific Biopharmaceuticals (ASX: NSB) has revealed the first pre-clinical res...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleOn Stockhead today: Aussie small caps trying to tackle the opioid crisis, which car manufacturers wi...
Read ArticleOn Stockhead today: our report on the 100 best performing stocks for the year, how four directors pu...
Read ArticleAt Stockhead we are as amazed as our readers when stocks rise by over 100 per cent in a day. But its...
Read ArticleThe Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price skyrocketed 190% on Tuesday after...
Read ArticleThe share price of Neuroscientific Biopharmaceuticals Ltd [ASX:NSB] is up a massive 175.86% trading...
Read ArticleAlzheimer’s treatment could be set for a significant boost following the publication of what NeuroSc...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
